What is Inovio Pharmaceuticals's latest dividend and current dividend yield?

What is the market's earnings forecast for Inovio Pharmaceuticals next quarter?

What were the key takeaways from Inovio Pharmaceuticals's earnings call?

What guidance did Inovio Pharmaceuticals's management provide for the next earnings period?

What does Inovio Pharmaceuticals do and what are its main business segments?

Did Inovio Pharmaceuticals beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Inovio Pharmaceuticals year over year?

What factors drove the changes in Inovio Pharmaceuticals's revenue and profit?

- **BLA Milestone Achieved**: INO-3107 BLA submission completed; FDA file acceptance expected by year-end with potential mid-2026 approval.
- **Cost Efficiency**: 22% YoY reduction in operating expenses; cash runway extended to Q2 2026.
- **Differentiated RRP Treatment**: INO-3107 avoids MRD surgeries during dosing, showing 78% reduction in surgeries vs. baseline.
- **Innovative Pipeline**: DMAb technology achieves durable antibody production; DPROT preclinical data for Factor VIII shows promise for hemophilia.

**【CEO Summary Section】**
 Inovio achieved a significant milestone with the completion of the rolling BLA submission for INO-3107 for recurrent respiratory papillomatosis (RRP) in October 2025. The company anticipates FDA file acceptance by year-end and has requested priority review, targeting a potential PDUFA date in mid-2026. Commercial preparations are advancing, with a focus on a patient-centric treatment regimen that avoids MRD surgeries during the dosing window. The CEO highlighted the potential of INO-3107 to become the preferred treatment due to its clinical efficacy and tolerability. Additionally, the company reported landmark proof-of-concept data for its DMAb technology in Nature Medicine, demonstrating durable antibody production, and upcoming preclinical DPROT data for Factor VIII at the World Federation of Hemophilia Global Forum.

**【CFO Financial Commentary】**
 - Q3 2025 operating expenses decreased 22% year-over-year to $21.2 million, driven by cost reduction initiatives.
 - Net loss was $45.5 million, primarily due to a $22.5 million non-cash loss on warrant liabilities.
 - Cash runway is projected to extend into Q2 2026, supporting ongoing development of INO-3107.

**【Q&A Key Highlights】**
 - **Market Positioning**: Despite Papzimeos' head start, Inovio expects single-digit penetration of the prevalent RRP population at launch, with the majority of patients available for treatment. The differentiated profile of INO-3107, including no MRD surgeries during dosing, is expected to drive preference.
 - **Regulatory Strategy**: The confirmatory trial design aligns with FDA guidance, with enrollment expected prior to approval. The trial will also support potential ex-U.S. filings.
 - **Switching from Papzimeos**: No cross-reactivity issues are anticipated, but patients would need to complete the full INO-3107 regimen.
 - **Pipeline Progress**: DMAb technology demonstrated sustained antibody production in a Phase I/II trial, and DPROT preclinical data for Factor VIII highlights potential for chronic disease treatment.


Inovio Pharmaceuticals, Inc. (INO) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

INO

INO fundamentals

You can ask Aime